Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIA Study of Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

NCT06734130 is registered in ClinicalTrials.gov with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor.

NCT NCT06734130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06734130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIA Study of Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 10, 2025
Completion date
January 31, 2029
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration sensitive prostate cancer